Yüklüyor......
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
SIMPLE SUMMARY: We reported that palbociclib plus exemestane with ovarian function suppression (with leuprolide) led to significantly longer median progression-free survival compared with capecitabine in premenopausal metastatic breast cancer patients. We also evaluated differences of patient report...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694364/ https://ncbi.nlm.nih.gov/pubmed/33167305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113265 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|